Key result
MSCT-based sizing for bicuspid TAVR links to an ~81% reduction in post-implantation AR.
Why the study?
Limited information exists describing the results and clinical outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease.
Is transcatheter aortic valve replacement feasible and safe in patients with bicuspid aortic valve disease?
Cohort (n=139)
Yes
Is transcatheter aortic valve replacement feasible and safe in patients with bicuspid aortic valve disease?
TAVR is feasible in patients with bicuspid aortic valve disease but carries a high risk of post-implantation aortic regurgitation, which can be significantly mitigated by using MSCT-based valve sizing.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It may sound self-evident, but not all bicuspid valves are the same. Treatment strategy and procedural outcomes are dictated by anatomy. Although most patients referred for aortic valve replacement in 2025 expect transcatheter therapy, bicuspid aortic valves often present anatomic features that make TAVR more challenging or less predictable—for example, bulky leaflet or annular calcification, calcium extending into the left ventricular outflow tract, or marked annular eccentricity. In such cases, surgical aortic valve replacement remains the preferred option—assuming the patient is otherwise at low surgical risk.”
“The results are overall very encouraging. The procedural outcomes support that TAVR is safe in bicuspid patients.”
“TAVR with a self-expanding prosthesis is a very viable and safe procedure in low-risk bicuspid patients and achieved excellent early results. Though additional follow-up is necessary to determine long-term outcomes, early results suggest this procedure can be performed successfully in low-risk individuals with a good outcome.”
TAVR in bicuspid aortic valve should not yet change practice despite MSCT reducing AR; leaves open pending randomized confirmation.
BACKGROUND: Limited information exists describing the results of transcatheter aortic valve (TAV) replacement in patients with bicuspid aortic valve (BAV) disease (TAV-in-BAV). OBJECTIVES: This study sought to evaluate clinical outcomes of a large cohort of patients undergoing TAV-in-BAV. METHODS: We retrospectively collected baseline characteristics, procedural data, and clinical follow-up findings from 12 centers in Europe and Canada that had performed TAV-in-BAV. RESULTS: A total of 139 patients underwent TAV-in-BAV with the balloon-expandable transcatheter heart valve (THV) (n = 48) or self-expandable THV (n = 91) systems. Patient mean age and Society of Thoracic Surgeons predicted risk of mortality scores were 78.0 ± 8.9 years and 4.9 ± 3.4%, respectively. BAV stenosis occurred in 65.5%, regurgitation in 0.7%, and mixed disease in 33.8% of patients. Incidence of type 0 BAV was 26.7%; type 1 BAV was 68.3%; and type 2 BAV was 5.0%. Multislice computed tomography (MSCT)-based TAV sizing was used in 63.5% of patients (77.1% balloon-expandable THV vs. 56.0% self-expandable THV, p = 0.02). Procedural mortality was 3.6%, with TAV embolization in 2.2% and conversion to surgery in 2.2%. The mean aortic gradient decreased from 48.7 ± 16.5 mm Hg to 11.4 ± 9.9 mm Hg (p < 0.0001). Post-implantation aortic regurgitation (AR) grade ≥ 2 occurred in 28.4% (19.6% balloon-expandable THV vs. 32.2% self-expandable THV, p = 0.11) but was prevalent in only 17.4% when MSCT-based TAV sizing was performed (16.7% balloon-expandable THV vs. 17.6% self-expandable THV, p = 0.99). MSCT sizing was associated with reduced AR on multivariate analysis (odds ratio [OR]: 0.19, 95% confidence intervals [CI]: 0.08 to 0.45; p < 0.0001). Thirty-day device safety, success, and efficacy were noted in 79.1%, 89.9%, and 84.9% of patients, respectively. One-year mortality was 17.5%. Major vascular complications were associated with increased 1-year mortality (OR: 5.66, 95% CI: 1.21 to 26.43; p = 0.03). CONCLUSIONS: TAV-in-BAV is feasible with encouraging short- and intermediate-term clinical outcomes. Importantly, a high incidence of post-implantation AR is observed, which appears to be mitigated by MSCT-based TAV sizing. Given the suboptimal echocardiographic results, further study is required to evaluate long-term efficacy.
No takes yet. Share an insight, caveat, or question.
Mylotte et al. (2014) conducted a cohort in Bicuspid aortic valve (BAV) disease (n=139). Transcatheter aortic valve replacement (TAV) was evaluated on Post-implantation aortic regurgitation (AR) grade ≥ 2 (OR 0.19, 95% CI 0.08 to 0.45, p=<0.0001). Transcatheter aortic valve replacement in bicuspid aortic valve disease is feasible, and MSCT-based sizing reduced post-implantation aortic regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: